Upon completion of primary therapy, women with low-grade serous carcinoma of the ovary (LGSOC) or peritoneum (LGSPC) who are under the age of 35 and have persistent disease face worse outcomes, according to a recent study published online ahead of print in the Journal of Clinical Oncology.
David Gershenson, MD, and fellow researchers at the University of Texas MD Anderson Cancer Center in Houston, TX, evaluated 350 patients who were diagnosed with stage 1 to 4 LGSOC or LGSPC before January 2012.
“LGSOC or LGSPC is a rare subtype of ovarian or peritoneal cancer characterized by young age at diagnosis and relative resistance to chemotherapy,” the authors noted. They hoped to validate these findings in the current study.
Continue Reading
Upon multivariate analysis, the researchers found that women over the age of 35 had a 43% reduced likelihood of dying compared to those 35 and younger.
RELATED: Reduced Chemotherapy Doses Linked to Decreased Survival in Ovarian Cancer
Additionally, having disease present upon completion of primary therapy was associated with a 1.78 increased hazard of dying compared to being clinically disease-free.
Women with LGSPC were found to have a 41% decreased likelihood of dying compared to those with LGSOC. “Patients with LGSPC seem to have a better prognosis than those with LGSOC,” the authors concluded.
Reference
- Gershenson DM, Bodurka DC, Lu KH, et al. Impact of age and primary disease site on outcome in women with low-grade serous carcinoma of the ovary or peritoneum: results of a large single-institution registry of a rare tumor. Journal of Clinical Oncology. [epub ahead of print]. doi: 10.1200/JCO.2015.61.0873.
